ALLR   $0.1724  -4.17% Market Closed

Allarity Therapeutics Inc
Last Events:

2023-07-18 Trend pattern changed from Not found to нисходящий клин.

2023-07-18 Signal in Stochastic changed from bearish to bearish recovery. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: entry into the oversold zone.

2023-05-18 Trend pattern changed from нисходящий клин to Not found.

2023-05-18 Signal in Stochastic changed from bearish recovery to bearish. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: entry into the oversold zone.

2023-05-16 Trend pattern changed from Not found to нисходящий клин.

2023-05-16 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-05-13 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-05-12 Trend pattern changed from нисходящий клин to Not found.


Current temperature: 0.93
ST: 0, Cor:

Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell - -
stoch - Sell -
ma20 Sell Sell -
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternJune 13, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US0167441049
ceo Mr. Thomas H. Jensen
Website https://www.allarity.com
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.